Service d'Oncologie Pédiatrique, Hôpital pour Enfants de "La Timone", Marseille, France.
Curr Cancer Drug Targets. 2010 Dec;10(8):879-89. doi: 10.2174/156800910793357899.
Tumor angiogenesis, i.e. the development of neovascularisation in and around solid tumors, plays a key role in the local and distant growth of cancer and anti-angiogenic treatments are now established strategies to treat cancer patients. Specific inhibitors of angiogenesis such as bevacizumab or receptor tyrosine kinase inhibitors targeting VEGFR or PDGFR are now in clinical trials and are being increasingly validated for the treatment of poor prognostic cancers. Other anti-angiogenic strategies such as cilengitide or metronomic chemotherapy (low-dose anti-angiogenic chemotherapy) have been developed to treat certain types of adult cancer. In children, the clinical potential of anti-angiogenic approach is still in an early stage of investigation. This review will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer.
肿瘤血管生成，即实体瘤及其周围新生血管的形成，在癌症的局部和远处生长中起着关键作用，抗血管生成治疗已成为癌症患者的一种既定治疗策略。贝伐单抗等血管生成特异性抑制剂或针对 VEGFR 或 PDGFR 的受体酪氨酸激酶抑制剂目前正在临床试验中，并越来越多地被验证可用于治疗预后不良的癌症。其他抗血管生成策略，如西仑吉肽或节拍化疗（低剂量抗血管生成化疗），已被开发用于治疗某些类型的成人癌症。在儿童中，抗血管生成方法的临床潜力仍处于研究的早期阶段。这篇综述将重点介绍血管生成在儿科实体瘤中的作用，并描述几种抗血管生成化合物的临床前和临床经验，这些化合物可能成为儿童癌症的一种潜在治疗方法。
